The U.S. Food and Drug Administration (FDA) approved an Abbreviated New Drug Application (ANDA) for Linagliptin And Metformin Hydrochloride on November 3, 2025. This approval marks the availability of a generic version of the combination drug, sponsored by MSN.
What this means
The FDA's approval of a generic version of Linagliptin And Metformin Hydrochloride on November 3, 2025, is a significant development for patients and the broader healthcare landscape. Generic medications play a crucial role in improving patient access to essential treatments by offering more affordable alternatives to brand-name drugs. This approval, granted to MSN, is expected to foster greater market competition, which typically leads to reduced prescription costs for consumers and healthcare providers. For clinicians, the availability of this generic option means more flexibility in prescribing, potentially easing the financial burden on patients who require treatment with this combination therapy. This event underscores the ongoing efforts by regulatory bodies to ensure a robust supply of cost-effective therapeutic options.
Source
The information regarding this approval was sourced from the U.S. Food and Drug Administration (FDA). The approval of Abbreviated New Drug Application ANDA208459 for Linagliptin And Metformin Hydrochloride was documented on November 3, 2025, and is publicly accessible on accessdata.fda.gov.